HANSOH PHARMA H1 2026 Profit Jumps 35.8% on Double-Digit Revenue Growth and Innovation Push

Bulletin Express09-23 17:44

HANSOH PHARMA (Hansoh Pharmaceutical Group Co. Ltd.) reported unaudited first-half 2026 revenue of RMB 8.30 billion, up 11.70 % year on year, driven by sustained expansion of its innovative medicines portfolio. Net profit rose 35.80 % to RMB 4.26 billion, lifting basic earnings per share to RMB 0.70, an increase of 33.10 %.

Innovative products contributed RMB 7.09 billion, accounting for 85.40 % of total sales, after climbing 15.40 % versus the prior-year period. Oncology remained the core therapeutic area, generating RMB 5.47 billion, or 65.90 % of group revenue. Non-oncology segments—including metabolism, immunology, CNS and anti-infectives—delivered RMB 2.83 billion, representing 34.10 % of revenue.

Research and development spending advanced 20.70 % to RMB 1.74 billion—20.90 % of revenue—as the company progressed more than 70 ongoing clinical trials covering over 40 pipeline assets. Key developments included the EU approval of Aumolertinib (Aumseqa) for EGFR-mutated NSCLC, NMPA acceptance of the NDA for Dalmelitinib plus Aumolertinib, and Breakthrough Therapy Designations for B7-H3 ADC HS-20093 across multiple cancer indications.

Operating cash flow reached RMB 2.34 billion, while capital expenditure totaled RMB 303 million, mainly for production facilities and R&D infrastructure. The balance sheet remained liquid with cash and bank balances of RMB 37.38 billion; the gearing ratio rose to 19.0 % after issuing HK$4.68 billion (approximately RMB 4.17 billion) zero-coupon convertible bonds in February 2026.

The board declared an interim dividend of HK$0.285 per share, payable on 29 October 2026 to shareholders on record as of 25 September 2026.

HANSOH PHARMA’s MSCI ESG rating was upgraded to AAA, placing the group in the top 1 % of Chinese pharmaceutical companies in S&P Global’s 2026 Sustainability Yearbook. Looking ahead, management targets accelerated global and domestic clinical filings, deeper hospital coverage for marketed drugs, and additional out-licensing and partnership opportunities to monetise its pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment